Jared Whitlock
Reporter
Phone: 858-634-4636 Extension: 3130
Recent Stories
Three Board Members Named to La Jolla Institute for Allergy and Immunology
La Jolla Institute for Allergy and Immunology has elected three new board members:
Heron Therapeutics’ Stock Surges on Clinical Data
A Heron Therapeutics postoperative pain anesthetic hit clinical trial targets in two additional areas, sending the company’s stock soaring.
Crinetics Pharmaceuticals Hires Chief Medical Officer
San Diego-based Crinetics Pharmaceuticals, focused on endocrine-related cancers and endocrine disorders, appointed Alan Krasner as chief medical officer.
Sharp Mary Birch Awarded $2.9M for 'Umbilical Cord Milking' Study
Sharp Mary Birch Hospital for Women & Newborns was awarded a $2.9 million grant to lead a multi-hospital, international study on a technique to increase the flow of blood from the umbilical cord into the infant’s circulatory system.
Vertex Pharmaceuticals Expands San Diego Footprint
Boston-based Vertex Pharmaceuticals has opened a 170,000-square-foot research facility in San Diego, more than doubling the company’s footprint locally.
Robotic Surgery Rides Tech Momentum Wave
MEDICINE: High Volume a Must; Adoption Becoming Norm
In San Diego hospitals, robots are on the rise, judging by splashy marketing and an increase in robotic surgery cases, per data obtained by the San Diego Business Journal.
Ionis Pharmaceuticals Hires New Chief Business Officer
Damien McDevitt has joined Carlsbad’s Ionis Pharmaceuticals as chief business officer.
Co. Creates, Facilitates CRO Marketplace
PHARMA: Scientist.com Doubles Revenue to $50M
Scientist.com reported $50.27 million in 2017 revenue, a whopping increase from $23.07 million in 2016 and $6 million in 2015.
UC San Diego Launches Center to Spark Anti-Parasitic Drugs
A new UC San Diego center is targeting an unmet need: parasitic infections hurting poor and underserved communities.
Senomyx Shareholder Calls for Sale of Co., Chair Resignation
A shareholder of San Diego-based biotech Senomyx is pushing for the company’s chairman to resign, an immediate company sale and a new board seat.